fashion -WSS

fashion

author：entertainment 2025-09-27 06:09:39 - browse：892

A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.

The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： ARCH Venture Partners tops STAT's 2023 biotech VC rankings

WSS

Readout Newsletter: BridgeBio, Akero, and human embryo models

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

The public health thinking behind the CDC’s new Covid guidance

At Orexo, a ‘turning point’ for everything but digital health

Sanofi seeks simpler, safer CRISPR sickle cell cure

Startup Neumora takes a novel depression drug to Phase 3

hotspot

fashion

entertainment

The cancer drug shortage isn’t new — and neither are the solutions

Key House panel plots a new health care package

At least 13 dead in Texas as scorching temps continue

Longer MASH drug regimen improved liver, Akero study finds

ChatGPT in medicine: STAT answers readers' burning questions

At Orexo, a ‘turning point’ for everything but digital health

Hollywood unions extend contract negotiations for actors

STAT Virtual Event: The State of Biosimilars: What to Watch

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Listen: Wegovy in the brain & pivotal Alzheimer's data

knowledge

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

Google and Epic fight stronger regulation of AI in health care

STAT Virtual Event: The State of Biosimilars: What to Watch

$1 billion proposal to grow Boston, Massachusetts biotech

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Harvard's David Sinclair gets blowback over aging

hotspot

focus

focus

hotspot